domingo, 21 de junio de 2020

Covid-19 and remdesivir: rethinking how we measure drug "value" - STAT

Covid-19 and remdesivir: rethinking how we measure drug "value" - STAT

First Opinion

Covid-19 and remdesivir: rethinking how we measure a drug’s ‘value’

By PATRICIA DEVERKA AND LOUIS GARRISON AND SAMUEL NUSSBAUM


ADOBE
Valuing new treatments like remdesivir should reflect cutting-edge assessment methods, reward innovation, and emphasize strategies to improve public health.

No hay comentarios: